Table IV.
Relationship between 21-gene RS and chemotherapeutic efficacy-related target genes.
| RS risk groups N (%)a | |||
|---|---|---|---|
| Chemotherapeutic efficacy-related target genes | Low risk (RS <18) | Intermediate/high risk (RS ≥18) | P-value |
| TYMS | 28.4 (1–89) | 45.8 (4.5–96) | 0.001 |
| RRM1 | 44.8 (1–98.1) | 43.5 (1–99) | 0.975 |
| TUBB3 | 39.6 (1–99) | 52.3 (0.8–99) | 0.337 |
| TOP2A | 35.9 (1.1–94.6) | 63.1 (2.7–98.1) | <0.001 |
| PTEN | 64.7 (7.9–99) | 65.6 (1.4–99) | 0.681 |
a
Median percentage of gene expression (range). Bold indicates P<0.05. PTEN, phosphatase and tensin homolog; RRM1, ribonucleotide reductase catalytic subunit M1; RS, recurrence score; TOP2A, DNA topoisomerase IIα; TUBB3, tubulin β3 class III; TYMS, thymidylate synthetase.